The randomized, double-blind, placebo-controlled, pilot phase 2 JUSTICE trial has been initiated to study the efficacy and safety of baricitinib, a JAK1/2-specific inhibitor, in reducing proteinuria in patients with APOL1-associated FSGS or HTN-CKD over a period of 6 months. Here, APOL1 is linked to focal segmental glomerulosclerosis.